Repare Therapeutics (NASDAQ:RPTX) Shares Down 3.2% on Disappointing Earnings

Repare Therapeutics Inc. (NASDAQ:RPTX) shares were down 3.2% during trading on Friday following a dissappointing earnings announcement. The stock traded as low as $30.19 and last traded at $31.19. Approximately 2,313 shares changed hands during trading, a decline of 98% from the average daily volume of 141,058 shares. The stock had previously closed at $32.21.

The company reported ($0.58) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.07).

Several equities analysts have commented on RPTX shares. Zacks Investment Research upgraded shares of Repare Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 17th. Morgan Stanley upped their price target on shares of Repare Therapeutics from $41.00 to $45.00 and gave the company an “overweight” rating in a research note on Monday, April 26th. Finally, Berenberg Bank began coverage on shares of Repare Therapeutics in a research report on Monday, March 8th. They set a “buy” rating and a $51.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $40.20.

In related news, CEO Lloyd Mitchell Segal sold 5,512 shares of the company’s stock in a transaction dated Thursday, April 15th. The shares were sold at an average price of $35.01, for a total value of $192,975.12. Following the transaction, the chief executive officer now directly owns 5,000 shares in the company, valued at $175,050. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Penserra Capital Management LLC acquired a new stake in Repare Therapeutics during the fourth quarter worth approximately $28,000. Citigroup Inc. bought a new stake in shares of Repare Therapeutics during the 4th quarter valued at $42,000. UBS Group AG grew its holdings in shares of Repare Therapeutics by 607.0% during the 1st quarter. UBS Group AG now owns 1,414 shares of the company’s stock worth $43,000 after purchasing an additional 1,214 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Repare Therapeutics in the first quarter worth $46,000. Finally, Wells Fargo & Company MN acquired a new position in Repare Therapeutics in the fourth quarter valued at about $87,000. Institutional investors own 64.81% of the company’s stock.

The business’s 50 day simple moving average is $31.76 and its 200-day simple moving average is $32.82.

Repare Therapeutics Company Profile (NASDAQ:RPTX)

Repare Therapeutics Inc, a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.

Featured Article: Discover Your Risk Tolerance

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.